Screener
Alnylam Pharmaceuticals ALNY Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Depreciation and amortization | 27,452 | 28,349 |
| Non-cash interest expense on liabilities related to the sale of future royalties and development funding | 145,279 | 112,307 |
| Stock-based compensation expense | 156,779 | 168,392 |
| Realized and unrealized loss on marketable equity securities | — | 2,306 |
| Deferred income taxes | 11,967 | 19,374 |
| Other | 11,272 | (37,864) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (142,023) | (144,347) |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's net gains (losses) on investments?
- Alnylam Pharmaceuticals (ALNY) reported net gains (losses) on investments of $0 in Q2 2026.
- How has Alnylam Pharmaceuticals's net gains (losses) on investments changed year-over-year?
- Alnylam Pharmaceuticals's net gains (losses) on investments increased by 100.0% year-over-year, from -$1.35M to $0.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about Alnylam Pharmaceuticals's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude